Browsing: FDA

Spruce Biosciences has received FDA Breakthrough Therapy designation for Tralesinidase Alfa (TA-ERT), an enzyme replacement therapy targeting Sanfilippo Syndrome Type B (MPS IIIB). This marks a pivotal advancement in rare disease treatment.